Biolife4D (SAVU), which is creating bioengineered human hearts for analysis and potential transplantation, has filed to carry a $17.3M preliminary public providing.
The biotech company’s filing didn’t disclose the quantity and pricing of the shares to be supplied, however mentioned that the deal would possible embody warrants and pre-funded warrants. A filing fee schedule indicated it was in search of to boost as much as $17.3M.
Biolife4D has utilized to listing its shares on Nasdaq underneath the image SAVU. Aegis Capital is serving as lead bookrunner.
Based mostly in Illinois, Biolife4D has been utilizing 3D bioprinting expertise to develop viable human hearts that might be used for analysis and potential transplantation. The corporate is at the moment engaged on creating a practical “mini-heart” that might be used for cardiotoxicity research.
A growth stage firm, Biolife4D reported no income for the quarter ended March 31, 2022.
After the providing, Biolife4D Founder, Chairman and Chief Govt Officer Steven Morris will management a majority of the voting energy of the corporate’s excellent frequent inventory.
For extra IPO information, try SA’s IPO News page.